Morningstar

Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts

We are holding steady to our fair value estimate and wide moat rating for Pfizer PFE following first-quarter results that largely matched our expectations. The company is tracking well to meet its ...

Is Pfizer stock a value trap or a generational opportunity?

Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

Pfizer Oncology Deal And Lung Cancer Data Reshape Valuation Debate

Pfizer (NYSE:PFE) has entered a global oncology partnership with Innovent Biologics worth up to $10.5b, focused on up to 12 ...

Better high-yield dividend stock to buy: Bristol Myers Squibb or Pfizer?

Durability, not yield, is the deciding factor.

Pfizer Oncology Partnerships Add Detail To Valuation And Earnings Concerns

Pfizer (NYSE:PFE) has entered a new alliance with Sarah Cannon Research Institute to accelerate oncology clinical trials and ...

Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

Prediction: Pfizer Will Beat the Market Over the Next 5 Years

Pfizer (PFE +0.19%) stock reached all-time highs earlier this decade thanks to the company's dominance in the market for coronavirus vaccines and medicines. However, the pharmaceu ...